Artivion, Inc. has acquired Endospan Ltd. for an undisclosed amount, marking a significant expansion in the cardiovascular medical device sector. This corporate acquisition brings Endospan's innovative NEXUS® Aortic Arch Stent Graft System under Artivion's umbrella. Endospan, a privately held company headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease.
Endospan's NEXUS® system is the only CE-approved off-the-shelf branched endovascular aortic arch system, designed to treat a wide range of aortic pathologies including arch aneurysms, thoracic dissections, and PAU. It offers a crucial minimally invasive alternative for patients diagnosed with dilative lesions in or near the aortic arch, who previously had limited options beyond invasive open-chest surgery with its associated risks and lengthy recovery periods. The NEXUS® "Dock and Lock" modular system provides stable anatomical anchoring and atraumatic sealing.
This acquisition is strategically important for Artivion, as it integrates a unique, market-ready solution into its portfolio, addressing a greatly underserved patient group. The addition of the NEXUS® system is expected to strengthen Artivion's presence in advanced endovascular therapies and expand its reach into the complex aortic arch segment. Synergies are anticipated through leveraging Artivion's existing infrastructure to accelerate the global commercialization and adoption of the NEXUS® technology.
The combined entity is poised to enhance patient access to this innovative treatment, offering a less invasive option for a challenging condition. This move underscores a commitment to advancing solutions for complex aortic diseases and improving patient outcomes worldwide.